Report
Grifols B : Q1 EBITDA a shade below, earnings significantly so. FY 2024 guidance reiterated
>Top line momentum deteriorated, partly explained by a tough Diagnostic comps. - Sales grew by +4% or +6% cc (vs +9% cc in Q4) to € 1.8bn, slightly below our numbers yet more aligned with the consensus. Biopharma posted +8% y-o-y growth or +9% cc (vs +10% cc in Q4) to € 1.5bn driven by a very solid trend on IG (+13%) and more specifically the SCIG (+62%cc explaining c.5% of IG sales) which were partly offset by a soft performance from Albumin (+7% cc) and Alpha1/other...
Underlying
Grifols S.A. Pref Class B
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.